Interaction between endogenous opioids and IL-2 on PHA-stimulated human lymphocytes

Area of Science:

• Immunology
• Neuroendocrinology
• Pharmacology

Background:

• Endogenous opioids modulate human lymphocyte functions, including natural killer (NK) cell activity.
• Opioid antagonist Naloxone can reverse opioid-induced NK cell function elevation.
• Lymphokines like interferon-alpha (IFN-alpha) and interleukin-2 (IL-2) also enhance NK cell activity, with suggested similarities to endogenous opioids.

Purpose of the Study:

• To investigate whether Naloxone modulates lymphokine-enhanced human NK activity.
• To explore the interaction between opioid and lymphokine receptors on human lymphocytes.

Main Methods:

• Assessed the effect of Naloxone on NK-enhancing activity of IFN-alpha and IL-2 in lymphocytes.
• Measured radiolabeled IL-2 receptor uptake and binding.
• Investigated the binding of labeled Naloxone to lymphocytes stimulated with phytohemagglutinin (PHA) in the presence of beta-endorphin or IL-2.

Main Results:

• Naloxone dose-dependently blunted the NK-enhancing effects of IFN-alpha and IL-2.
• Naloxone reduced the uptake of radiolabeled IL-2 receptors.
• Beta-endorphin decreased the binding of radiolabeled IL-2 or IL-2 receptor-positive lymphocytes.
• Labeled Naloxone binding was inhibited by beta-endorphin or IL-2 on PHA-stimulated lymphocytes.

Conclusions:

• Human lymphocyte receptors for opioids, IFN, or IL-2 influence each other upon occupation.
• These findings support a role for central nervous system (CNS)-mediated influences on the human immune system.
• Suggests a complex interplay between opioid and lymphokine signaling pathways in immune regulation.